These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35582303)

  • 21. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
    Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
    Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study.
    Wang Q; Fang Y; Li C; Leong TL; Provencio M; Oh IJ; Zhang Z; Su C
    Transl Lung Cancer Res; 2023 Feb; 12(2):312-321. PubMed ID: 36895937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
    ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Sun C; Zhou F; Li X; Zhao C; Li W; Li J; Xiong A; Yu J; Gao G; Wang Q; Wu F; Zhou C
    Onco Targets Ther; 2020; 13():12777-12786. PubMed ID: 33363383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression.
    Chen C; Xiong X; Cheng Y; Gen H; Zhu W; Zhang F; Zhu C; Han S; Liu X
    Front Immunol; 2023; 14():1266992. PubMed ID: 37781406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
    Kano H; Ichihara E; Harada D; Inoue K; Kayatani H; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Ninomiya K; Hotta K; Maeda Y; Kiura K
    Cancer Sci; 2020 Oct; 111(10):3739-3746. PubMed ID: 32726470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
    Dai L; Jin B; Liu T; Chen J; Li G; Dang J
    EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
    Front Oncol; 2021; 11():732214. PubMed ID: 34557415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Ren P; Liu D; Li W
    Cancer Med; 2019 Jul; 8(8):4023-4031. PubMed ID: 31165589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
    Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
    J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Nov; 8(54):93149-93155. PubMed ID: 29190984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
    Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients.
    Heo JY; Yoo SH; Suh KJ; Kim SH; Kim YJ; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
    Sci Rep; 2021 Jan; 11(1):2514. PubMed ID: 33510255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
    Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study.
    Guven DC; Yekeduz E; Erul E; Yazgan SC; Sahin TK; Karatas G; Aksoy S; Erman M; Yalcin S; Urun Y; Kilickap S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3599-3606. PubMed ID: 35960374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.